2023 World Conference on Lung Cancer (Posters)-EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody

EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC) who had previously been treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies. The researchers retrospectively reviewed patients at a medical center in Kyoto, Japan, who had received combination immunotherapy between November 2020 and November 2022. Among the 67 patients who received nivolumab plus ipilimumab, 27 had previously received anti-PD-1 and/or anti-PD-L1 immunotherapy. The objective response rate was 14.8%, and the disease control rate was 48.1% for the re-immunotherapy regimen. The highest grade of immune-related adverse events was grade 3, which occurred in 11.1% of cases. Based on these findings, the researchers concluded that re-immunotherapy with nivolumab plus ipilimumab may be feasible and provide clinical benefits in selected patients who have received prior immunotherapy. However, further prospective studies are needed to determine which patients may benefit the most from re-immunotherapy.

Asset Subtitle

Zentaro Saito

Meta Tag

Speaker Zentaro Saito

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

re-immunotherapy

nivolumab

ipilimumab

NSCLC

anti-PD-1

anti-PD-L1

retrospective review

objective response rate

disease control rate

immune-related adverse events